Celgene Provides REVLIMID® Regulatory Update

[Business Wire] – BOUDRY, Switzerland–(BUSINESSWIRE)– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that REVLIMID ® (lenalidomide) has been granted full approval, which … more

View todays social media effects on CELG

View the latest stocks trending across Twitter. Click to view dashboard

See who Celgene is hiring next, click here to view